• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

57.40 -7.59 (-11.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
Today 9:00 EDT
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
Today 9:00 EDT
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
March 03, 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation at Upcoming Investor Conferences
February 05, 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
January 08, 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in December Investor Conferences
November 25, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan
November 21, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
November 21, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in November Investor Conferences
November 04, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
November 10, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
October 29, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
October 13, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
September 29, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
September 29, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in September Investor Conferences
August 27, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
June 03, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
May 27, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Stock Repurchase Plan
March 24, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in March Investor Conferences
February 27, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
February 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 11, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
February 03, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
February 03, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap